Philip P. Connor

Hamburg, HH, DE 
Hamburg, HH, DE 

Overview

Philip Connor practices practicing medicine in Hamburg, Germany.

His clinical expertise encompasses Dubin-Johnson Syndrome, Immune Thrombocytopenic Purpura (ITP), Purpura, and Thrombocytopenia.

He is actively involved in clinical research, co-authoring 156 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Hamburg, HH, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase 2b Placebo-Controlled Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess Immunological Response and Safety of a Single Dose BPZE1 With/Without Coadministration of Tdap (Boostrix™)
Phase 2b Placebo-Controlled Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess Immunological Response and Safety of a Single Dose BPZE1 With/Without Coadministration of Tdap (Boostrix™)
Enrollment Status: Completed
Publish Date: November 06, 2025
Intervention Type: Biological
Study Phase: Phase 2
International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia
International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia
Enrollment Status: Terminated
Publish Date: May 11, 2023
Intervention Type: Drug
Study Drugs: Selumetinib, Dexamethasone
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

156 Total Publications

EARLY RESPONSE AND GENETICS DEFINE RELAPSE RISK AFTER FRONTLINE BLINATUMOMAB IN CHILDHOOD B-ALL: A COHORT STUDY.
EARLY RESPONSE AND GENETICS DEFINE RELAPSE RISK AFTER FRONTLINE BLINATUMOMAB IN CHILDHOOD B-ALL: A COHORT STUDY.
Journal: Blood advances
Published: May 07, 2026

Frequently Asked Questions about Philip P. Connor

Is Philip P. Connor a top-rated expert for Dubin-Johnson Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Philip P. Connor is classified as an Experienced expert for Dubin-Johnson Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Philip P. Connor participate in research or clinical trials?

Yes. Philip P. Connor has published 156 articles and abstracts on conditions like Dubin-Johnson Syndrome. You can view a list of Philip P. Connor's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Connor's expertise for a condition
ConditionClose
        View All 16 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile